Interviews

William G. Wierda, MD, PhD, discusses the synergy between ibrutinib and venetoclax in patients with chronic lymphocytic leukemia.

Srdan Verstovsek, MD, PhD, discusses the impacts of an analysis demonstrating longer survival in patients with myelofibrosis who received ruxolitinib versus those who didn’t.

Sara A. Hurvitz, MD, discusses sequencing the current therapies for patients with HER2-positive breast cancer.

Scott R. Solomon, MD, discusses the adverse events and pharmacokinetics of lisocabtagene maraleucel in 12 patients with relapsed/refractory large B-cell non-Hodgkin lymphoma who had previously received anti-CD19 therapy.

Matthew T. Campbell, MD, MS, discusses trials investigating cabozantinib in patients with renal cell carcinoma.

Michael R. Charlton, MD, MBBS, discusses the impact of the LEGACY trial investigating yttrium-90 radioembolization in patients with solitary, unresectable hepatocellular carcinoma.

Arun Azad, MBBS, PhD, discusses ongoing studies of lutetium-177-PSMA radionuclide in patients with prostate cancer.

Tycel J. Phillips, MD, discusses the design and responses at 8 weeks in a phase 2 trial of parsaclisib in patients with relapsed/refractory marginal zone lymphoma.

Bradley McGregor, MD, discusses the ongoing COSMIC-313 trial of cabozantinib, ipilimumab, and nivolumab in patients with renal cell carcinoma.

Naveen Pemmaraju, MD, discusses the results of combining ruxolitinib and navitoclax in different high-risk populations of relapsed/refractory myelofibrosis.

Neeraj Agarwal, MD, discusses the possible adverse events of the randomized phase 3 CONTACT-02 trial of cabozantinib plus atezolizumab versus a second novel hormonal therapy in patients with metastatic castration-resistant prostate cancer.

Sairah Ahmed, MD, discusses the continued investigations of axicabtagene ciloleucel, a chimeric antigen receptor T-cell therapy used in multiple types of lymphoma.

Othman Al-Sawaf, MD, discusses an analysis of minimal residual disease in patients with chronic lymphocytic leukemia given venetoclax and obinutuzumab on the CLL14.

Debu Tripathy, MD, discusses escalation and de-escalation of treatment in patients with HER2-positive breast cancer with HER2-targeted agents and chemotherapy.

Adam M. Brufsky, MD, PhD, discusses the use of neoadjuvant therapy for patients with triple–negative breast cancer.

Brian I. Rini, MD, discusses the dosing of nivolumab plus ipilimumab for patients with renal cell carcinoma.

Lucia Masarova, MD, discusses the efficacy of CPI-0610 in the phase 2 MANIFEST trial in patients with myelofibrosis.

Kami Maddocks, MD, discusses potential treatments in follicular lymphoma.

William G. Wierda, MD, PhD, discusses challenges faced in when investigating ibrutinib and venetoclax in the CAPTIVATE trial for patients with chronic lymphocytic leukemia.

Andrew Spencer, MD, MBBS, discusses the PANORAMA 3 trial data of oral panobinostat plus subcutaneous bortezomib and dexamethasone versus placebo, bortezomib, and dexamethasone.

Al B. Benson, MD, discusses concerns in the hepatocellular carcinoma setting for treating patients for the best outcomes.

Ulka N. Vaishampayan, MBBS, FAB, discusses the updated data from CheckMate 214 of nivolumab and ipilimumab versus sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma.

Danielle Hammond, MD, discusses the results from a retrospective review of patients with acute myeloid leukemia treated over the last 6 years with a combination of venetoclax and either decitabine or azacitadine.

Halle Moore, MD, discusses the results of the IBIS-II DCIS trial of anastrozole versus tamoxifen after 12 years of follow-up for postmenopausal patients with locally excised ductal carcinoma in situ.

Andrew Wei, MBBS, PhD, discusses the results from the phase 3 QUAZAR AML-001 Maintenance Trial of CC-486 for patients with acute myeloid leukemia in the first remission after intensive chemotherapy.

Jesus G. Berdeja, MD, discusses the findings from the phase 2 results of ciltacabtagene autoleucel as treatment of patients with relapsed/refractory multiple myeloma in the CARTITUDE-1 study.

Amitkumar Mehta, MD, discusses the toxicity profile of parsaclisib in the phase 2 CITADEL-205 clinical trial of relapsed/refractory mantle cell lymphoma.

Kerry Rogers, MD, discusses the findings observed in the phase 1b study of ianalumab in combination with ibrutinib as treatment of patients with chronic lymphocytic leukemia on ibrutinib therapy.

Mark J. Roschewski, MD, discusses the preliminary results of a phase 2 trial of copanlisib and rituximab as treatment of patients with untreated follicular lymphoma.

Andrew X. Zhu, MD, PhD, discusses the final results from the phase 3 ClarIDHy study of ivosidenib versus placebo as treatment of patients with previously treated cholangiocarcinoma and an IDH1 mutation.